Translational Drug Development (TD2)
Damaris Diaz has extensive work experience in the pharmaceutical and research fields. Damaris began their career as a Senior Research Assistant at WRAIR in 2004 and worked there until 2006. Damaris then joined Merck as a Staff Chemist from 2006 to 2009. In 2009, they joined Lexicon Pharmaceuticals and held positions as an Associate Scientist and later a Scientist until 2014. Since 2014, they have been working at Translational Drug Development (TD2). At TD2, they have held roles as a Senior Scientist in DMPK and currently serves as the Associate Director of Laboratory Operations. Overall, Damaris Diaz has accumulated a wealth of experience in laboratory operations, DMPK, and scientific research.
Damaris Diaz began their education at the Universidad de Cartagena in Colombia from 1992 until 1998, where they earned a degree as a Pharmaceutical Chemist. Damaris later pursued a Master's degree in Pharmacology from the Universidad de Antioquia, which they obtained from 1999 to 2001.
This person is not in any teams
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.